Search Results 321-330 of 17251 for GLP-1 therapy
... 1 trial. Phase 4 trials look at long-term safety ... - Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. ... - Prior treatment with an ...
Participation eligibility · Medical need for chronic acetaminophen · Use of any glucose-lowering agent (such as Pramlintide, Metformin, GLP-1 analogs, SGLT2 ...
... 1-drug regimen. The primary outcome measures of trial are to evaluate several components indicating immunologic problems with the transplanted organ at 1 ...
The medical research study tested gene therapy in pigs suffering from hereditary tyrosinemia type 1 (HT1), a metabolic disorder caused by an enzyme deficiency.
... treatment works better than the current standard therapy. ... 1 trial. Phase 4 ... Current or planned use of glucose lowering medication, including GLP-1 ...
The prevalence of LQTS is about 1 in 2,000. If ... "Our novel suppression-replacement gene therapy ... Ackerman notes that therapies such as beta blockers and ...
... treatment works better than the current standard therapy. ... The purpose of this study is to evaluate ALPN-202 with PD-1 ... PD-1 inhibitors: one scheduled ...
... (1) Cohort 1 focuses on cancers displaying a high (80-90%) frequency of MUC1 ... therapy; (2) if patient is already engaged in an ongoing cyclical systemic therapy ...
Thorvardur Halfdanarson, a Mayo Clinic medical oncologist. “Not only can they arise anywhere in the body, but they behave very differently from one person to ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!